Prize in sight for LENZ’s eye drop for near vision

LENZ Therapeutics (Nasdaq: LENZ), a US biopharma focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, is a step closer to realizing its ambition.

The San Diego-based firm has announced positive top-line results from its Phase III CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

With LNZ100, which has been selected as the lead candidate, the primary endpoint was met, with 71% of participants dosed with the drops achieving three-lines or greater improvement at three hours.